193 related articles for article (PubMed ID: 1315233)
1. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Barrett MS; Jones RN; Erwin ME; Koontz FP
Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of quinolones and macrolides against mycobacteria.
Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
[TBL] [Abstract][Full Text] [Related]
3. In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
Shen GH; Wu BD; Wu KM; Chen JH
Antimicrob Agents Chemother; 2007 May; 51(5):1849-51. PubMed ID: 17353252
[TBL] [Abstract][Full Text] [Related]
4. Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
Koontz FP; Erwin ME; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1994 Jul; 19(3):183-6. PubMed ID: 7821001
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
7. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Wanger A; Boulet B; Plaunt M; Brown BA; Wallace RJ
J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Tomioka H; Saito H; Sato K
Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
[TBL] [Abstract][Full Text] [Related]
9. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
10. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
Gui J; Wang F; Hong CY; Li JL; Liang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
[TBL] [Abstract][Full Text] [Related]
11. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
Abshire R; Cockrum P; Crider J; Schlech B
Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
[TBL] [Abstract][Full Text] [Related]
12. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
Pellegrin I; Maugein J; Lapeyre C; Barbeau P; Leng B; Pellegrin JL
J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
Saito H; Tomioka H; Sato K; Dekio S
Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Disratthakit A; Doi N
Antimicrob Agents Chemother; 2010 Jun; 54(6):2684-6. PubMed ID: 20368403
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
Yajko DM; Sanders CA; Nassos PS; Hadley WK
Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.
Texier-Maugein J; Mormède M; Fourche J; Bébéar C
Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050
[TBL] [Abstract][Full Text] [Related]
18. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Forstall GJ; Knapp CC; Washington JA
Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
[TBL] [Abstract][Full Text] [Related]
19. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.
Khardori N; Nguyen H; Rosenbaum B; Rolston K; Bodey GP
Antimicrob Agents Chemother; 1994 Jan; 38(1):134-7. PubMed ID: 8141567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
